David B Liesenfeld1, Nina Habermann1, Reka Toth1, Robert W Owen1, Eva Frei1, Jürgen Staffa1, Petra Schrotz-King1, Karel D Klika2, Cornelia M Ulrich1,3. 1. Division of Preventive Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany and German Consortium for Translational Cancer Research (DKTK). 2. Genomics and Proteomics Core Facility, Molecular Structure Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington.
Abstract
Introduction: Metabolomics is a valuable tool for biomarker screening of colorectal cancer (CRC). In this study, we profiled the urinary metabolomes of patients enrolled in a prospective patient cohort (ColoCare). We aimed to describe changes in the metabolome in the longer clinical follow-up and describe initial predictors as candidate markers with possibly prognostic significance. Methods: In total, 199 urine samples from CRC patients pre-surgery (n=97), 1-8 days post-surgery (n=12) and then after 6 and 12 months (n=52 and 38, respectively) were analyzed using both GC-MS and 1H-NMR. Both datasets were analyzed separately with built in uni- and multivariate analyses of Metaboanalyst 2.0. Furthermore, adjusted linear mixed effects regression models were constructed. Results: Many concentrations of the metabolites derived from the gut microbiome were affected by CRC surgery, presumably indicating a tumor-induced shift in bacterial species. Associations of the microbial metabolites with disease stage indicate an important role of the gut microbiome in CRC.We were able to differentiate the metabolite profiles of CRC patients prior to surgery from those at any post-surgery timepoint using a multivariate model containing 20 marker metabolites (AUCROC=0.89; 95% CI:0.84-0.95). Conclusion: To the best of our knowledge, this is one of the first metabolomic studies to follow CRC patients in a prospective setting with repeated urine sampling over time. We were able to confirm markers initially identified in case-control studies and pin point metabolites which may serve as candidates for prognostic biomarkers of CRC.
Introduction: Metabolomics is a valuable tool for biomarker screening of colorectal cancer (CRC). In this study, we profiled the urinary metabolomes of patients enrolled in a prospective patient cohort (ColoCare). We aimed to describe changes in the metabolome in the longer clinical follow-up and describe initial predictors as candidate markers with possibly prognostic significance. Methods: In total, 199 urine samples from CRC patients pre-surgery (n=97), 1-8 days post-surgery (n=12) and then after 6 and 12 months (n=52 and 38, respectively) were analyzed using both GC-MS and 1H-NMR. Both datasets were analyzed separately with built in uni- and multivariate analyses of Metaboanalyst 2.0. Furthermore, adjusted linear mixed effects regression models were constructed. Results: Many concentrations of the metabolites derived from the gut microbiome were affected by CRC surgery, presumably indicating a tumor-induced shift in bacterial species. Associations of the microbial metabolites with disease stage indicate an important role of the gut microbiome in CRC.We were able to differentiate the metabolite profiles of CRC patients prior to surgery from those at any post-surgery timepoint using a multivariate model containing 20 marker metabolites (AUCROC=0.89; 95% CI:0.84-0.95). Conclusion: To the best of our knowledge, this is one of the first metabolomic studies to follow CRC patients in a prospective setting with repeated urine sampling over time. We were able to confirm markers initially identified in case-control studies and pin point metabolites which may serve as candidates for prognostic biomarkers of CRC.
Entities:
Keywords:
Biomarkers; Colorectal cancer; Gas chromatography-mass spectrometry (GC-MS); Gut microbiome; Metabolomics; Nuclear magnetic resonance (NMR); Patient cohort; Prospective design
Authors: Daniel Scharlau; Anke Borowicki; Nina Habermann; Thomas Hofmann; Stefanie Klenow; Claudia Miene; Umang Munjal; Katrin Stein; Michael Glei Journal: Mutat Res Date: 2009-04-19 Impact factor: 2.433
Authors: Julian R Marchesi; Bas E Dutilh; Neil Hall; Wilbert H M Peters; Rian Roelofs; Annemarie Boleij; Harold Tjalsma Journal: PLoS One Date: 2011-05-24 Impact factor: 3.240
Authors: Hans-Ulrich Kauczor; Cornelia M Ulrich; Caroline Himbert; Jennifer Ose; Johanna Nattenmüller; Christy A Warby; Andreana N Holowatyj; Jürgen Böhm; Tengda Lin; Mariam Haffa; Biljana Gigic; Sheetal Hardikar; Dominique Scherer; Lin Zielske; Petra Schrotz-King; Torsten Kölsch; Erin M Siegel; David Shibata; Alexis Ulrich; Martin Schneider; Stephen D Hursting Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-17 Impact factor: 4.254
Authors: David B Liesenfeld; Akke Botma; Nina Habermann; Reka Toth; Christoph Weigel; Odilia Popanda; Karel D Klika; John D Potter; Johanna W Lampe; Cornelia M Ulrich Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-11-19 Impact factor: 4.254
Authors: Mahmoud Delphan; Tengda Lin; David B Liesenfeld; Johanna Nattenmüller; Jürgen T Böhm; Biljana Gigic; Nina Habermann; Lin Zielske; Petra Schrotz-King; Martin Schneider; Alexis Ulrich; Hans-Ulrich Kauczor; Cornelia M Ulrich; Jennifer Ose Journal: Metabolomics Date: 2018-01-31 Impact factor: 4.290
Authors: Fan Zhang; Yuanyuan Zhang; Weiwei Zhao; Kui Deng; Zhuozhong Wang; Chunyan Yang; Libing Ma; Margarita S Openkova; Yan Hou; Kang Li Journal: Oncotarget Date: 2017-05-23
Authors: Anne J M R Geijsen; Eline H van Roekel; Fränzel J B van Duijnhoven; David Achaintre; Thomas Bachleitner-Hofmann; Andreas Baierl; Michael M Bergmann; Jürgen Boehm; Martijn J L Bours; Hermann Brenner; Stéphanie O Breukink; Stefanie Brezina; Jenny Chang-Claude; Esther Herpel; Johannes H W de Wilt; Audrey Gicquiau; Biljana Gigic; Tanja Gumpenberger; Bibi M E Hansson; Michael Hoffmeister; Andreana N Holowatyj; Judith Karner-Hanusch; Pekka Keski-Rahkonen; Eric T P Keulen; Janna L Koole; Gernot Leeb; Jennifer Ose; Peter Schirmacher; Martin A Schneider; Petra Schrotz-King; Anton Stift; Arve Ulvik; F Jeroen Vogelaar; Evertine Wesselink; Moniek van Zutphen; Andrea Gsur; Nina Habermann; Ellen Kampman; Augustin Scalbert; Per M Ueland; Alexis B Ulrich; Cornelia M Ulrich; Matty P Weijenberg; Dieuwertje E Kok Journal: Int J Cancer Date: 2019-10-10 Impact factor: 7.396